191 related articles for article (PubMed ID: 25648959)
1. Impact of fumaric acid esters on cardiovascular risk factors and depression in psoriasis: a prospective pilot study.
Schmieder A; Poppe M; Hametner C; Meyer-Schraml H; Schaarschmidt ML; Findeisen P; Benoit S; Bauer B; Schmid S; Goebeler M; Goerdt S; Ludwig-Peitsch WK
Arch Dermatol Res; 2015 Jul; 307(5):413-24. PubMed ID: 25648959
[TBL] [Abstract][Full Text] [Related]
2. Treatment of severe, recalcitrant, chronic plaque psoriasis with fumaric acid esters: a prospective study.
Wain EM; Darling MI; Pleass RD; Barker JN; Smith CH
Br J Dermatol; 2010 Feb; 162(2):427-34. PubMed ID: 19519838
[TBL] [Abstract][Full Text] [Related]
3. Fumaric acid esters in combination with a 6-week course of narrowband ultraviolet B provides an accelerated response compared with fumaric acid esters monotherapy in patients with moderate-to-severe plaque psoriasis: a randomized prospective clinical study.
Tzaneva S; Geroldinger A; Trattner H; Tanew A
Br J Dermatol; 2018 Mar; 178(3):682-688. PubMed ID: 29114862
[TBL] [Abstract][Full Text] [Related]
4. Systemic therapy of plaque-type psoriasis ameliorates endothelial cell function: results of a prospective longitudinal pilot trial.
Boehncke S; Fichtlscherer S; Salgo R; Garbaraviciene J; Beschmann H; Diehl S; Hardt K; Thaçi D; Boehncke WH
Arch Dermatol Res; 2011 Aug; 303(6):381-8. PubMed ID: 21170539
[TBL] [Abstract][Full Text] [Related]
5. Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study.
Mrowietz U; Christophers E; Altmeyer P
Br J Dermatol; 1998 Mar; 138(3):456-60. PubMed ID: 9580799
[TBL] [Abstract][Full Text] [Related]
6. Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study.
Boehncke S; Salgo R; Garbaraviciene J; Beschmann H; Hardt K; Diehl S; Fichtlscherer S; Thaçi D; Boehncke WH
J Eur Acad Dermatol Venereol; 2011 Oct; 25(10):1187-93. PubMed ID: 21241371
[TBL] [Abstract][Full Text] [Related]
7. Fumaric acid esters in severe psoriasis, including experience of use in combination with other systemic modalities.
Balasubramaniam P; Stevenson O; Berth-Jones J
Br J Dermatol; 2004 Apr; 150(4):741-6. PubMed ID: 15099371
[TBL] [Abstract][Full Text] [Related]
8. Disparate effects of adalimumab and fumaric acid esters on cardiovascular risk factors in psoriasis patients: results from a prospective, randomized, observer-blinded head-to-head trial.
Holzer G; Hoke M; Sabeti-Sandor S; Perkmann T; Rauscher A; Strassegger B; Radakovic S; Tanew A
J Eur Acad Dermatol Venereol; 2021 Feb; 35(2):441-449. PubMed ID: 32426884
[TBL] [Abstract][Full Text] [Related]
9. Fumaric acid esters for psoriasis: a systematic review.
Smith D
Ir J Med Sci; 2017 Feb; 186(1):161-177. PubMed ID: 27271164
[TBL] [Abstract][Full Text] [Related]
10. Fumaric acid esters for severe psoriasis: a retrospective review of 58 cases.
Harries MJ; Chalmers RJ; Griffiths CE
Br J Dermatol; 2005 Sep; 153(3):549-51. PubMed ID: 16120141
[TBL] [Abstract][Full Text] [Related]
11. Glutathione-S-transferase T1 genotyping and phenotyping in psoriasis patients receiving treatment with oral fumaric acid esters.
Gambichler T; Kreuter A; Susok L; Skrygan M; Rotterdam S; Höxtermann S; Müller M; Tigges C; Altmeyer P; Lahner N
J Eur Acad Dermatol Venereol; 2014 May; 28(5):574-80. PubMed ID: 23489263
[TBL] [Abstract][Full Text] [Related]
12. Methotrexate vs. fumaric acid esters in moderate-to-severe chronic plaque psoriasis: data registry report on the efficacy under daily life conditions.
Inzinger M; Weger W; Heschl B; Salmhofer W; Quehenberger F; Wolf P
J Eur Acad Dermatol Venereol; 2013 Jul; 27(7):861-6. PubMed ID: 22672248
[TBL] [Abstract][Full Text] [Related]
13. Fumaric acid esters for the treatment of psoriasis in Germany: characterising patients in routine care.
Mrowietz U; Sorbe C; Reich K; Von Kiedrowski R; Weckbecker J; Radtke MA; Rustenbach SJ; Augustin M
Eur J Dermatol; 2020 Feb; 30(1):41-48. PubMed ID: 32250255
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis.
Hoefnagel JJ; Thio HB; Willemze R; Bouwes Bavinck JN
Br J Dermatol; 2003 Aug; 149(2):363-9. PubMed ID: 12932244
[TBL] [Abstract][Full Text] [Related]
15. Progressive multifocal leukoencephalopathy associated with fumaric acid esters treatment in psoriasis patients.
Balak DMW; Hajdarbegovic E; Bramer WM; Neumann HAM; Thio HB
J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):1475-1482. PubMed ID: 28322482
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of fumaric acid esters in children with psoriasis: a retrospective analysis of 14 patients from The Netherlands.
Balak DM; Oostveen AM; Bousema MT; Venema AW; Arnold WP; Seyger MM; Thio HB
Br J Dermatol; 2013 Jun; 168(6):1343-7. PubMed ID: 23738641
[TBL] [Abstract][Full Text] [Related]
17. Proteinuria with fumaric acid ester treatment for psoriasis.
Ogilvie S; Lewis Jones S; Dawe R; Foerster J
Clin Exp Dermatol; 2011 Aug; 36(6):632-4. PubMed ID: 21771009
[TBL] [Abstract][Full Text] [Related]
18. Long-term real-life safety profile and effectiveness of fumaric acid esters in psoriasis patients: a single-centre, retrospective, observational study.
Dickel H; Bruckner T; Altmeyer P
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1710-1727. PubMed ID: 29705996
[TBL] [Abstract][Full Text] [Related]
19. Immunological changes in psoriasis patients under long-term treatment with fumaric acid esters: risk of Kaposi sarcoma occurrence?
Philipp S; Kokolakis G; Hund M; Witte E; Witte K; Kunz S; Roewert HJ; Sterry W; Sabat R
Eur J Dermatol; 2013; 23(3):339-43. PubMed ID: 23774790
[TBL] [Abstract][Full Text] [Related]
20. Fumaric acid esters suppress peripheral CD4- and CD8-positive lymphocytes in psoriasis.
Höxtermann S; Nüchel C; Altmeyer P
Dermatology; 1998; 196(2):223-30. PubMed ID: 9568412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
